

<b>INFORMATION DISCLOSURE CITATION TYPE</b>	ATTY. DOCKET NO.	SERIAL NO.
	249-255	10/089,500
(Use several sheets if necessary)	APPLICANT	GROUP
	ANAI et al	1643
FILING DATE		
March 29, 2002		

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DB	5,091,178	02/1992	Hellstrom et al.	—	—	
↓	5,730,981	03/1998	Bosslet et al.	—	—	
↓	5,610,280	03/1997	Brandt et al.	—	—	
DB	5,006,470	04/1991	Yamaguchi et al.	—	—	

## FOREIGN PATENT DOCUMENTS

	DOCUMENT	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
DB	0 280 209 A2	08/1988	Europe	—	—		
↓	0 493 686 A1	07/1992	Europe	—	—		
↓	0 867 190 A1	09/1998	Europe	—	—		
DB	0 533 199 A2	03/1993	Europe	—	—		

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

DB	Ojima et al, Tohoku J. Exp. Med., 1998, Vol. 185, No. 2, pp 89-100
	Shitara et al, Cancer Immunol Immunother, 1993, Vol. 36, No. 6, pp 373-380
	Scott et al, Current Opinion in Immunology, 1997, Vol. 9, No. 5, pp 717-722
	Alpaugh et al, Medical Oncology, 1998, Vol. 15, No. 3, pp 191-198
	Nasi et al, Melanoma Research, 1997, Vol. 7, No. suppl 2, pp S155-S162
	Chapman et al, Cancer Immunol Immunother, 1994, Vol. 39, No. 3, pp 198-204
	Dippold et al, European Journal of Cancer, 1992, Vol. 28A, No. 10, pp 1605-1610
	A Process for the Production of Humanized Chimaeric Antibody, Current Opinion in Therapeutic Patents, 993, Vol. 3, No. 9, pp 1357-1358
↓	Supplementary European Search Report dated August 18, 2005 issued in corresponding
DB	EP 00 96 2981.7

Examiner	/David Blanchard/	Date Considered	04/25/2006
----------	-------------------	-----------------	------------

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

Form PTO-FB-A820 (Also PTO-1449)